Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages

Wang, Xin; Wang, Han; Yin, Guosheng; Zhang, Yan Dora

doi:10.1016/j.heliyon.2023.e14059

Cited by 7 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Erlotinib has effective inhibitory effect on T cell activation and proliferation 126 . Erlotinib also affects the interaction of viral proteins with cytokines and cytokine receptors by targeting EGFR 127 …”

Section: Significance Of Targeting Egfr Signaling In Covid‐19mentioning

confidence: 99%

“…126 Erlotinib also affects the interaction of viral proteins with cytokines and cytokine receptors by targeting EGFR. 127 Furthermore, AAK1, a potent regulator of endocytosis, facilitates SARS-CoV-2 entry into host cells. 128 In COVID-19, the inhibition of AAK1 may suppress intracellular assembly and spread of virus particles in host cells.…”

Section: Erlotinib As a Promising Antiviral Drug For Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19

Razzaq,

Disoma,

Zhou

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously producing new variants, necessitating effective therapeutics. Patients are not only confronted by the immediate symptoms of infection but also by the long‐term health issues linked to long COVID‐19. Activation of epidermal growth factor receptor (EGFR) signalling during SARS‐CoV‐2 infection promotes virus propagation, mucus hyperproduction, and pulmonary fibrosis, and suppresses the host's antiviral response. Over the long term, EGFR activation in COVID‐19, particularly in COVID‐19‐induced pulmonary fibrosis, may be linked to the development of lung cancer. In this review, we have summarised the significance of EGFR signalling in the context of SARS‐CoV‐2 infection. We also discussed the targeting of EGFR signalling as a promising strategy for COVID‐19 treatment and highlighted erlotinib as a superior option among EGFR inhibitors. Erlotinib effectively blocks EGFR and AAK1, thereby preventing SARS‐CoV‐2 replication, reducing mucus hyperproduction, TNF‐α expression, and enhancing the host's antiviral response. Nevertheless, to evaluate the antiviral efficacy of erlotinib, relevant clinical trials involving an appropriate patient population should be designed.

show abstract

Section: Significance Of Targeting Egfr Signaling In Covid‐19mentioning

confidence: 99%

Section: Erlotinib As a Promising Antiviral Drug For Covid-19mentioning

confidence: 99%

Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19

Razzaq,

Disoma,

Zhou

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…As of September 2023, the global rate of SARS-CoV-2 infections remains high, with seroprevalence studies showing that> 80% of the population of countries such as South Africa have already been infected ( Hajissa et al, 2022 ). The treatment strategies for COVID-19 depend on its stage and should be tailored to the specific stage of the disease that a patient is experiencing ( Stasi et al, 2020 ; Wang et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Dastan,

Jamaati,

Barati

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized COVID-19 patients with an inflammatory status. However, the effects of co-administering these medications aiming for more rapid patient recovery are controversial among practitioners. The potential benefits include the rapid improvement of patients and regulation of the immune system, and the potential risks include the increased chance of serious adverse events, including infections. This study aimed to investigate the effects of co-administering these two medications on the 28-day mortality rate, other efficacy parameters, and safety issues.Methods: In this randomized open-label trial, 68 patients were recruited. The study was conducted at Dr. Masih Daneshvari Hospital during 6 months (from 21 March 2022 to 23 August 2022). Severely ill patients aged between 18 and 100 years old with confirmed COVID-19 were enrolled. The primary outcomes included the need for invasive mechanical ventilation and a 28-day mortality rate. Secondary outcomes included the need for non-invasive mechanical ventilation, the need for admission to the intensive care unit (ICU), the length of hospital stay, and the need for a second dose of tocilizumab. Safety assessments were also performed for 28 days. The data were collected from the patients’ medical records, which included age, gender, and comorbidities.Results: The 28-day mortality rate or the need for mechanical ventilation was not statistically different among the two groups (p-value = 0.49 for both outcomes). The need for non-invasive mechanical ventilation, the need for admission to the ICU, or the need for a second dose of tocilizumab and the length of hospital stay was not affected either (p-value = 1; 0.1; 0.49 and 0.9, respectively). One patient developed thrombosis in the combination group. No adverse events related to infectious complications were recorded in any groups.Conclusion: This study showed no beneficial effects of combining tocilizumab and baricitinib in managing severe COVID-19 cases. However, the need for ICU admission was meaningfully lower in the combination group. Studies with larger sample sizes are needed to confirm these results.Clinical Trial Registration: Identifier: RCT20151227025726N30M

show abstract

Machine Learning Applications for Drug Repurposing

Yingngam

2024

Artificial Intelligence and Machine Learning in Drug Design and Development

View full text Add to dashboard Cite

Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages

Cited by 7 publications

References 56 publications

Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19

Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Machine Learning Applications for Drug Repurposing

Contact Info

Product

Resources

About